research use only

Doxercalciferol Vitamin chemical

Name: Doxercalciferol
Brand: Selleck Chemicals
SKU: S1467
Rating: 5 (4 reviews)

Cat.No.S1467

Doxercalciferol (1α-hydroxyvitamin D2) is a synthetic Vitamin D2 analog, suppressing parathyroid synthesis and secretion, used to treat secondary hyperparathyroidism and Metabolic bone disease.

Chemical Structure

Molecular Weight: 412.65

Jump to

Quality Control

Batch: Purity: 99.99%

99.99

Related Targets	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Carbohydrate Metabolism Mitochondrial Metabolism Drug Metabolite
Other Vitamin Inhibitors	Trolox Sodium ascorbate D-Pantethine Amprolium HCl Nicotinic Acid Ergosterol Pyridoxal phosphate D-Pantothenate Sodium Thiamine pyrophosphate hydrochloride Fursultiamine

Chemical Information, Storage & Stability

Molecular Weight	412.65	Formula	C₂₈H₄₄O₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	54573-75-0	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	1α-hydroxyvitamin D2			Smiles	CC(C)C(C)C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C

Solubility

In vitro
Batch:

DMSO : 83 mg/mL (201.13 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 70 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vivo

Doxercalciferol (100 or 300 pg/g b.w.) normalises serum calcium and parathyroid hormone (PTH) levels in nephrectomy treated mice. This compound (300 pg/g b.w.) significantly reduces osteitis fibrosa in nephrectomy treated mice. It results in significant decrease in cardiac hypertrophy and improves cardiac function in rats fed a high salt (HS) diet. This treatment leads to a significant decrease in plasma brain natriuretic peptide (BNP) level and tissue atrial natriuretic factor (ANF) mRNA level in rats fed a high salt (HS) diet. It also significantly reduces the level of protein kinase C-α (PKCα) suggesting that PKC-mediated cardiac hypertrophy may be associated with Vitamin D deficiency. This chemical decreases proteinuria, podocyte injury, mesangial expansion, and extracellular matrix protein accumulation in Diet-induced obesity (DIO) mice. It also decreases macrophage infiltration, oxidative stress, proinflammatory cytokines, and profibrotic growth factors in DIO mice. It also prevents the activation of the renin-angiotensin-aldosterone system including the angiotensin II type 1 receptor and the mineralocorticoid receptor in DIO mice. This compound combined with Losartan most effectively prevents albuminuria, restored glomerular filtration barrier structure, and dramatically reduces glomerulosclerosis in a dose-dependent manner in mice. This combination virtually prevents morphological and molecular changes in diabetic kidneys of mice.

References

[1] https://pubmed.ncbi.nlm.nih.gov/21849802/
[2] https://pubmed.ncbi.nlm.nih.gov/22123370/
[3] https://pubmed.ncbi.nlm.nih.gov/21209008/

[4] https://pubmed.ncbi.nlm.nih.gov/19535571/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00792857	Completed	Chronic Kidney Disease\|Secondary Hyperparathyroidism\|Chronic Renal Insufficiency\|Chronic Renal Failure	OPKO IP Holdings II Inc.\|OPKO Health Inc.	November 2008	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):